MedTrace Logo

Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy

NCT01258686 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2013-11-25

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of silymarin 700 mg thrice daily and assess the safety in patients with hepatitis C virus infection compared to a placebo.

Conditions

  • Hepatitis C

Interventions

DRUG

Silymarin

700mg thrice daily

DRUG

Placebo

Placebo 700mg thrice daily

Sponsors & Collaborators

  • Bukwang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Byung Chul Yoo, MD. PhD. · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-11-30
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01258686 on ClinicalTrials.gov